Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Antifungal prophylaxis in leukemia patients
The importance of multiple myeloma foundations and a patient story
Paul Richardson et al.
Benefits of deacetylase inhibitors for leukemia therapy
The structure IC-APL and how it is helping APL patients in developing countries